{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:51:12Z","timestamp":1790135472981,"version":"4.0.1"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,11,15]],"date-time":"2006-11-15T00:00:00Z","timestamp":1163548800000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Pathology"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:p>Adenosine A<jats:sub>2A<\/jats:sub>receptors (A<jats:sub>2A<\/jats:sub>R) are highly expressed in striatum. However, they are also present in extrastriatal structures. A<jats:sub>2A<\/jats:sub>R were studied in post\u2010mortem human frontal cortex from Pick\u2019s disease (PiD) and age\u2010matched non\u2010demented controls by radioligand binding assays, Western\u2010blotting, real\u2010time PCR and adenylyl cyclase activity determination. Saturation binding assay using [<jats:sup>3<\/jats:sup>H]ZM 241385, a selective A<jats:sub>2A<\/jats:sub>antagonist, as radioligand revealed a significant increase in total adenosine A<jats:sub>2A<\/jats:sub>R numbers (B<jats:sub>max<\/jats:sub>) in frontal cortex from PiD samples (191% of control B<jats:sub>max<\/jats:sub>), suggesting up\u2010regulation of this receptor. A significant increase in the level of A<jats:sub>2A<\/jats:sub>R was also detected by Western\u2010blotting. Furthermore, expression of mRNA coding A<jats:sub>2A<\/jats:sub>R determined by quantitative real\u2010time PCR was enhanced. In agreement, stimulation of adenylyl cyclase by CGS 21680, a selective A<jats:sub>2A<\/jats:sub>receptor agonist, was significantly strengthened. Up\u2010regulation of A<jats:sub>2B<\/jats:sub>receptors and their corresponding mRNA was also observed. These results show that A<jats:sub>2A<\/jats:sub>adenosine receptor\/adenylyl cyclase transduction pathway is up\u2010regulated and sensitized in frontal cortex brain from PiD.<\/jats:p>","DOI":"10.1111\/j.1750-3639.2006.00026.x","type":"journal-article","created":{"date-parts":[[2006,11,16]],"date-time":"2006-11-16T02:41:54Z","timestamp":1163644914000},"page":"249-255","source":"Crossref","is-referenced-by-count":34,"title":["Adenosine A<sub>2A<\/sub>Receptors are Up\u2010regulated in Pick\u2019s Disease Frontal Cortex"],"prefix":"10.1111","volume":"16","author":[{"given":"Jos\u00e9 Lu\u00eds","family":"Albasanz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairena","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,11,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07983.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00899-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2003.tb00475.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s004010000283","article-title":"Distinct isoform of tau aggregated in neurons and glial cells in brains of patients with Pick\u2019s disease, corticobasal generation and progressive spranuclear palsy","volume":"101","author":"Arai T","year":"2001","journal-title":"Acta Neuropathol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00401-003-0671-8","article-title":"Different immunoreactivities of the microtubule\u2010binding region of tau and its molecular basis in brains from patients with Alzheimer\u2019s disease, Pick\u2019s disease, progressive supranuclear palsy and corticobasal degeneration","volume":"105","author":"Arai T","year":"2003","journal-title":"Acta Neuropathol (Berl)"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(00)00019-9"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh128"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-005-0649-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00082.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jnen.0000171649.86718.f2"},{"issue":"43","key":"e_1_2_6_12_2","first-page":"23","article-title":"Adenosine: an endogenous neuroprotective metabolite and neuromodulator","author":"Deckert J","year":"1994","journal-title":"J Neural Transm"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(98)00108-6"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199602000-00004"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1998.tb00158.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.24.1.31"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10248"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0031-6997(24)01396-6","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use","volume":"51","author":"Fredholm BB","year":"1999","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1211\/0022357011775631"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(05)63007-3"},{"key":"e_1_2_6_21_2","first-page":"507","article-title":"Neocortical morphometry and cholinergic neurochemistry in Pick\u2019s disease","volume":"131","author":"Hansen LA","year":"1988","journal-title":"Am J Pathol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0993-1026"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90211-5"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb14240.x"},{"key":"e_1_2_6_25_2","first-page":"217","article-title":"Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors","volume":"16","author":"Ji XD","year":"1999","journal-title":"Drug Des Discov"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/10799899209074789"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf119"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000095219.22086.31"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.09.052"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702591"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01008.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2004.11.028"},{"key":"e_1_2_6_33_2","first-page":"145","volume-title":"Neuropathology of Dementing Disorders","author":"Markesbery WR","year":"1998"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(91)90038-P"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(00)00033-3"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.7.965"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005326"},{"key":"e_1_2_6_38_2","first-page":"970","article-title":"125I\u20104\u2010(2\u2010[7\u2010amino\u20102\u2010[2\u2010furyl][1,2,4]triazolo [2,3\u2010a][1,3,5] triazin\u20105\u2010yl\u2010amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor","volume":"48","author":"Palmer TM","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.04.029"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb15923.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0031-6997(24)01373-5","article-title":"Receptors for purines and pyrimidines","volume":"50","author":"Ralevic V","year":"1998","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1210\/mend-5-8-1037"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1358\/dnp.2003.16.2.740246"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(97)86055-X"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(92)90141-R"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(95)00152-2"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.10.040"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(01)00343-8"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164104225016182"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164105X21896"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90533-L"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.027"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb04967.x"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(83)90200-9"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64390-8"}],"container-title":["Brain Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1750-3639.2006.00026.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1750-3639.2006.00026.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T23:22:42Z","timestamp":1736637762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1750-3639.2006.00026.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1111\/j.1750-3639.2006.00026.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1750-3639.2006.00026.x","archive":["Portico"],"relation":{},"ISSN":["1015-6305","1750-3639"],"issn-type":[{"value":"1015-6305","type":"print"},{"value":"1750-3639","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}